With over 75% of Policy Labs subscribers suffering from medical conditions associated with obesity, GLP-1 treatment options and clinical studies have been a hot but confusing topic amongst the user base
Were here to help.
Collectively, real-world evidence strongly validates the effectiveness of GLP-1 RAs in decreasing MALOs in patients with MASLD and type 2 diabetes
These are not guaranteed for every person, but they represent the clinical reasons for the avoidance recommendation
Grosicki GJ, Flatt AA, Cross BL, Vondrasek JD, Blumenburg WT, Lincoln ZR, Chall A, Bryan A, Patel RP, Ricart K, Linder BA, Sanchez SO, Watso JC, Robinson AT
Gearhardt, A